Table 2 Potentially eligible published trials identified by AFFIRM’s systematic review
Study name & first author | Year | Country & sample size | Participants | Intervention & control | Relevant outcomes | Comment re: inclusion in IPDMA |
|---|---|---|---|---|---|---|
ETHIG II *Schleussner [35] | Abstract 2013 | Germany N = 449 | Recurrent pregnancy loss | Dalteparin 5000 IU + vitamins vs multivitamins | Intact pregnancy at 24 wks GA; PE; IUGR <5th percentile; abruption | Yes |
Giancotti [36] | 2012 | Italy N = 167 (pregnant) | Recurrent pregnancy loss | Enoxaparin 40 mg vs Enoxaparin 40 mg + ASA vs ASA | Live births | Not eligible (All losses <12 weeks GA) |
Salman [37] | Abstract 2012 | Egypt N = 150 | Recurrent pregnancy loss | Tinzaparin 4500 IU vs folic acid | Continuation of pregnancy after 20 weeks | Not eligible (All women with early losses) |
HABENOX [38] Visser | 2011 | Finland, Sweden, Netherlands N = 207 | Women with recurrent early or late miscarriage | Enoxaparin 40 mg vs Enoxaparin 40 mg + ASA vs ASA | Live birth rate; PE; IUGR <2 SD; abruption | Yes |
SPIN [39] Clark | 2010 | UK, New Zealand N = 294 | Recurrent pregnancy loss | Enoxaparin 40 mg + ASA vsno drug | Pregnancy loss | GA of past losses not available centrally |
ALIFE [40] Kaandorp | 2010 | Netherlands N = 299 (pregnant) | Recurrent pregnancy loss | Nadroparin 2850 IU + ASA vs ASA vs placebo | Pregnancy loss, SGA <10th percentile; PE; HELLP; abruption | Yes |
HepASA [41] Laskin | 2009 | Canada N = 88 Terminated at interim analysis | Recurrent pregnancy loss | Dalteparin 5000 IU + ASA vs ASA | Live births | Unable to contact |